Abstracts

231 – Inflammatory Monocyte and T-Cell Signatures Linked to IL-1β, a Marker of Vascular Risk in HIV

Background People with HIV (PWH) on antiretroviral therapy (ART) often experience persistent immune activation despite viral suppression. IL-1β, a potent pro-inflammatory cytokine, has been implicated in vascular disease and atherogenesis. Here, we stratified ART-treated PWH by plasma IL-1β levels and investigated immune cell transcriptional profiles to uncover mechanisms that may link IL-1β to increased vascular…

818 – Pre-ART Vertical HIV Transmission Rates in Uganda Vary by Sex of Child and Maternal Viral Subtype

Background In adults, HIV-1 subtype A is associated with higher rates of heterosexual transmission, whereas subtype D is linked to faster disease progression. Less is known about the impact of subtype in perinatal transmission, although data indicate a greater susceptibility of female infants to perinatal acquisition. Here, we evaluated the impact of infant sex and…

837 – Impact of Early Treatment Initiation After Perinatal HIV Infection on Intact Provirus Levels

Background Early ART initiation in children with perinatal HIV-1 infection reduces significantly the overall reservoir size. However, few studies assessed its impact on reservoir composition, particularly genetically intact, potentially replication-competent proviruses. From the ANRS-MIE-EP59 CLEAC study, we investigated whether early ART initiation affects reservoir intactness during childhood and adolescence. Methods The study included children (5-12 yrs) and…

1036 – Doxycycline Postexposure Prophylaxis Impact on Neisseria gonorrhoeae Antimicrobial Susceptibility

Background Antimicrobial resistance in gonorrhea is a growing concern. Doxycycline post-exposure prophylaxis (DoxyPEP) has been proposed to reduce bacterial sexually transmitted infections (STIs). Aim is to assess DoxyPEP impact on gonorrhea antimicrobial susceptibility. Methods This is a retrospective study including people with culture-positive gonorrhea infections diagnosed between 2022-2025 at San Raffaele Institute, Milan, Italy. Minimum inhibitory…

586 – Resistance Analysis of Weekly Islatravir Plus Lenacapavir in People With HIV-1 at 96 Weeks

Background Islatravir (ISL), a nucleoside reverse transcriptase translocation inhibitor, and lenacapavir (LEN), an approved capsid inhibitor, have potent anti-HIV-1 activities and pharmacokinetic profiles enabling once-weekly (QW) oral dosing. GS-US-563-6041 (NCT05052996) is a Phase 2, open-label study evaluating QW ISL+LEN in virologically suppressed people with HIV-1 (PWH). All participants maintained virologic suppression (VS; HIV-1 RNA <50 copies/mL…

612 – Impact of Rapid Testing and Self-Administered Risk Questionnaires on Hepatitis C Screening Rates

Background Underdiagnosis remains a major barrier to Hepatitis C (HCV) elimination. The ATENEA study assesses whether the implementation of rapid testing combined with a self-administered risk assessment in Primary Care (PC) settings could enhance HCV detection. Methods This is a cluster-randomized, stepped-wedge trial (clinicaltrials.gov ID: NCT06528626) conducted across eight PC centers between July 2023 and…